Britain and America have concluded a major commercial pact that will guarantee zero duties on British medicine products going into the American market.
Key Provisions of the Deal
As part of the deal, the UK has agreed to increase expenditure on drugs through the public health system. This move ensures that import taxes on these crucial exports will be held at zero for a period of the next three years.
This agreement follows earlier warnings to hike duties on branded drug products, with figures discussed reaching 100%.
"This deal between the United Kingdom bolsters the global environment for cutting-edge drugs and brings long-overdue equity to American-British drug exports," a statement said.
Trade Significance
Drugs are one of the Britain's most significant exports to the United States, which is easily the biggest market for major companies like GSK and AstraZeneca.
Trade data show that in the one-year period leading up to last September, the UK exported drugs valued at over eleven billion pounds to the US. This amount made up a significant portion of total UK exports in that timeframe.
"This agreement safeguards employment, boosts capital expenditure and sets the stage for the UK to emerge as a worldwide center for medical research," a government official remarked.
Key British Pledges
The pact involves several specific commitments from the British government:
- Revised Affordability Limit: The UK will increase the price threshold at which it judges new treatments to be unaffordable by 25%.
- Boosted Medicine Funding: There is a aim to double total NHS spending on drugs from 0.3% of GDP to 0.6 percent over the coming ten years.
- Rebate Cap: The amount pharmaceutical firms must pay back to the NHS to stay within budget will be restricted at fifteen percent. In the past, repayments were more than twenty percent.
Broader Context
The deal takes place against a ongoing tension between the drug companies and the UK government over medicine costs and regulatory access.
This friction were intensified by assertions that US patients were charged a premium for the same drugs than consumers in the Britain and the EU.
Over the last 18 months, several large drug company projects in the UK have been halted or scrapped, while multi-billion-dollar investments have been announced toward American operations.
The Science Minister stated that the NHS had to spend more on drugs, noting that its expenditure on drugs had decreased as a proportion of its resources over the previous ten-year period.
